

IN THE CLAIMS:

Please add the following new claims:

Sub F31 / --121. A method of treating a patient having an epithelial skin condition, comprising topically applying to the skin of said patient, a therapeutically effective amount of a compound, wherein in an *in vitro* bioassay, said compound inhibits a Keratinocyte Growth Factor (KGF) protein having the amino acid sequence of Figure 7 from stimulating epithelial cell mitogenesis.

122. The method of claim 121, wherein said compound comprises an active ingredient that is selected from the group consisting of an antibody, a fragment of an antibody, a DNA probe, heparin and a peptide that is based upon said antibody.

FI 123. The method of claim 121, wherein said epithelial skin condition is psoriasis.

124. The method of claim 121, wherein said compound is in a pharmaceutical composition comprising a pharmaceutically acceptable carrier.

125. The method of claim 121, wherein said bioassay is the BALB/MK bioassay.

Sub F32 / 126. An method of treating a patient having an epithelial skin condition comprising administering to said patient a therapeutically effective amount of a compound to treat said condition, wherein in an *in vitro* assay, said compound inhibits a Keratinocyte Growth Factor protein having the amino acid sequence of Figure 7 from stimulating epithelial cell mitogenesis.

127. The method of claim 126, wherein said compound comprises an active ingredient that is selected from the group consisting of an antibody, a fragment of an antibody, a DNA probe, heparin and a peptide that is based upon said antibody.

128. The method of claim 126, wherein said bioassay is the BALB/MK bioassay.